Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib
Author Information
Author(s): Billemont B, Medioni J, Taillade L, Helley D, Meric J B, Rixe O, Oudard S
Primary Institution: Pitie-Salpetriere Hospital, Paris, France
Hypothesis
Several mechanisms could be involved in the blood glucose level variations associated with sunitinib therapy in patients treated for metastatic renal cell carcinoma.
Conclusion
Sunitinib treatment is associated with a decrease in blood glucose levels in patients with type II diabetes.
Supporting Evidence
- All 19 patients with type II diabetes had a decrease in blood glucose level after 4 weeks of treatment.
- Five patients normalized their blood glucose levels after two cycles of sunitinib.
- Blood glucose levels in non-diabetic control patients showed no significant variation during treatment.
Takeaway
This study found that a cancer drug called sunitinib can lower blood sugar levels in people with diabetes.
Methodology
The study retrospectively reviewed blood glucose level variations in 200 patients treated with sunitinib for metastatic renal cell carcinoma.
Limitations
The study is retrospective and may not account for all variables affecting blood glucose levels.
Participant Demographics
Patients included 19 with type II diabetes and 9 non-diabetic controls, with a mean age of 62 for diabetics and 57 for non-diabetics.
Statistical Information
P-Value
0.04
Confidence Interval
95% CI: 8.14
Statistical Significance
p=0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website